

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



MAY 11, 2004 3:27PM

AVENTIS US PAT DEPT

NO. 2668 P. 3

# PATENT

Docket No.: DEAV2002/0070 US NP

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  
Klingler, et al.

Examiner:

Art Unit: 1614

Application No.: 10/700,273

Filed: November 3, 2004

Title: Novel Pyrimidine-4,6-dicarboxylic acid  
Diamides for Selectively Inhibiting Collagenases

I hereby certify that this correspondence is being  
transmitted via facsimile to the Commissioner for  
Patents, P. O. Box 1450, Alexandria, VA 22313-1450,  
at (703) 746-4060, on

May 11, 2004  
Date of Deposit  
\_\_\_\_\_  
Signature

## REQUEST FOR CORRECTED FILING RECEIPT

Mail Stop Missing Parts  
Commissioner of Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Attached is a copy of the official Filing Receipt from the Patent and Trademark Office in the above-identified application, for which issuance of a corrected filing receipt is respectfully requested.

There is an error in that the filing date listed is incorrect. The correct filing date is November 3, 2003, not November 4, 2003. Attached is a copy of the postcard receipt wherein the filing date is properly indicated as November 3, 2003.

There is an error in that the Title of the Application is incorrect. Please delete the "collagnases" and replace with --collagenases--. Therefore, the corrected title should read as follows:

"Novel Pyrimidine-4,6-dicarboxylic acid Diamides for Selectively Inhibiting Collagenases."

Page 1 of 2  
May 11, 2004

MAY. 11. 2004 3:28PM

AVENTIS US PAT DEPT

NO. 2668 P. 4

The Commissioner is hereby authorized to charge any fees that are required by this paper to  
Deposit Account 18-1982.

Respectfully submitted,

May 11, 2004

  
Julie Anne Knight, Reg. No. 48,867  
Attorney for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-3679  
Telefax (908) 231-2626

Aventis Docket No. DEAV2002/0070 US NP

Page 2 of 2  
May 11, 2004



MAY 11 2004 3:28PM

AVENTIS US PAT DEPT

NO. 2668 P. 5



## UNITED STATES PATENT AND TRADEMARK OFFICE


UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address COMMISSIONER FOR PATENTS  
P.O. Box 1459  
Alexandria, Virginia 22304-0459  
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/700,273	11/04/2003	1614	770	DEAV20020070USNP		12	1

05487  
ROSS J. OEHLER  
AVENTIS PHARMACEUTICALS INC.  
ROUTE 202-206  
MAIL CODE: D303A  
BRIDGEWATER, NJ 08807

CONFIRMATION NO. 4505

## FILING RECEIPT



\*OC000000011904634\*

SAK / J. then  
COMPUTER ENTERED  
Jes 2/19/04

Date Mailed: 02/13/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Otmar Klingler, Rodgau, GERMANY;  
Reinhard Kirsch, Braunschweig, GERMANY;  
Joerg Habermann, Ariccia, ITALY;  
Klaus-Ulrich Weithmann, Hofheim, GERMANY;  
Christian Engel, Frankfurt, GERMANY;  
Bernard Pirard, Darmstadt, GERMANY;

## Assignment For Published Patent Application

AVENTIS PHARMA DEUTSCHLAND GMBH, Frankfurt, GERMANY;

## Domestic Priority data as claimed by applicant

This appln claims benefit of 60/456,395 03/21/2003  
and claims benefit of 60/458,316 03/28/2003

## Foreign Applications

GERMANY 102 51 019.9 11/02/2002  
GERMANY 102 54 092.6 11/20/2002

ACTION DUE	Filing Receipt - Request Correct
DUE DATE	3/1/04
DKTD BY	Jes 2/26/04
ATTY	SAK

If Required, Foreign Filing License Granted: 02/13/2004

Projected Publication Date: To Be Determined - pending completion of Missing Parts

**Non-Publication Request:** No

**Early Publication Request:** No

**Title**

Novel Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases

**Preliminary Class**

514

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



APPLICANTS <b>KLINGLER, et al.</b>	SERIAL NO. <b>NOT Yet Assigned</b>	DATE <b>11/03/03</b>
DOCKET NO. <b>DEAV2000/0000 US NP</b>	ATTY <b>JAK</b>	
APPLICANT(S)		
TITLE OF INVENTION <b>NOVEL PYRIMIDINE-4,6-DICARBOXYLIC ACID DIAMIDES FOR SELECTIVELY INHIBITING COLLAGNASES</b>		

The Patent Office acknowledges and has stamped hereon the date of receipt of the filing of the application.

<input type="checkbox"/> Affidavit/Declaration, 37 CFR	<input type="checkbox"/> Maintenance fee transmittal
<input type="checkbox"/> Amendment, 37 CFR	<input checked="" type="checkbox"/> Patent Application
<input type="checkbox"/> Appeal notice/appeal Brief	<input type="checkbox"/> Total # of pages (Spec and claims)
<input type="checkbox"/> Assignment & Cover Sheet	<input type="checkbox"/> # of sheets of drawings
<input type="checkbox"/> Cert. of correction request	<input checked="" type="checkbox"/> Declaration/Oath: signed <input checked="" type="checkbox"/> unsigned
<input checked="" type="checkbox"/> Cert. of Exp. Mailing, <b>NO. EL 96482304 US</b>	<input checked="" type="checkbox"/> Transmittal letter
<b>Date: November 3, 2003</b>	<input checked="" type="checkbox"/> Power of Attorney
<input checked="" type="checkbox"/> Charge deposit account, in duplicate	<input checked="" type="checkbox"/> Abstract <b>1 # of pages</b>
<input type="checkbox"/> Check \$ _____ for _____	<input type="checkbox"/> PCT Application, transmittal, request & fee sheet
<input type="checkbox"/> Demand for PCT examination	<input type="checkbox"/> Petition under 37 CFR <b>17548 U.S. PTO</b>
<input type="checkbox"/> Extension of time petition	<input type="checkbox"/> Power of attorney <b>10/700273</b>
<input checked="" type="checkbox"/> IDS (information disclosure statement) <b>x 2 pages</b>	<input type="checkbox"/> Priority claim
PTO Form 1449: <input checked="" type="checkbox"/> # of pages enc. <b>2 pages</b>	<input type="checkbox"/> Reply, 37 CFR <b>110303</b>
# of reference enc. <b>9</b>	<input checked="" type="checkbox"/> Other Application Data Sheet
<input type="checkbox"/> Issue fee transmittal & advance order	<b>Certified copies of DE 102 51 019.9 and DE 102 54 092.6</b>
	PTO Date Stamp and Return



MAY 11 2004 3:29PM

AVENTIS US PAT DEPT

NO. 2668 P. 8

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
**KLINGLER, et al.**

Examiner:

Art Unit: 1614

Application No.: 10/700,273

Filed: November 3, 2003

Title: **NOVEL PYRIMIDINE-4,6-  
DICARBOXYLIC ACID DIAMIDES  
FOR SELECTIVELY INHIBITING  
COLLAGENASES**

I hereby certify that this correspondence is being  
transmitted via facsimile to the Commissioner for  
Patents, P. O. Box 1450, Alexandria, VA 22313-1450,  
at (703) 746-4060, on

May 11, 2004  
Date of Deposit

Rene M. Ginnio  
Signature

**REPLY TO NOTICE OF MISSING PARTS  
UNDER 37 C.F.R. 1.53(f)**

Mail Stop Missing Parts  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

In response to the "NOTICE TO FILE MISSING PARTS OF APPLICATION - FILING  
DATE GRANTED" which was mailed on February 13, 2004, and which indicated that the oath or  
declaration was missing, Applicants submit herewith the Declaration for the present application and  
a copy of Form PTO-1533.


A Power of Attorney by two authorized Signatories of AVENTIS PHARMA DEUTSCHLAND  
GMBH, Assignee of full rights and title to the above-identified application, is also enclosed.

A Request for Corrected Filing Receipt, to correct the filing date and Title of the invention,  
accompanied by a copy of the postcard receipt, is also enclosed.

Please charge the \$130.00 fee involved to Deposit Account No. 18-1982. The Commissioner is hereby authorized to charge any additional fees which may be required by this paper, or credit any overpayment to Account No. 18-1982. Two duplicate copies of this sheet are enclosed.

Respectfully submitted,

*May 11, 2004*

  
Julie Anne Knight, Reg. No. 48,867  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-3679  
Telefax (908) 231-2626

Docket No. DEAV2002/0070 US NP